Neuro‐Metabolic Association in Alzheimer’s Disease and Obesity: Clinical Evaluation of NA‐831 and NA‐931

Abstract

Background: This study explores the potential link between Alzheimer’s disease (AD) and obesity by evaluating two oral drugs: NA‐831 is a novel drug candidate with neuroprotective, neurogenic, and memory‐enhancing properties for the treatment of Alzheimer’s Disease (AD).

The paper